Literature DB >> 15668709

Papillomavirus infection in rural women in southern India.

S Franceschi1, R Rajkumar, P J F Snijders, A Arslan, C Mahé, M Plummer, R Sankaranarayanan, J Cherian, C J L M Meijer, E Weiderpass.   

Abstract

To investigate the prevalence of, and the risk factors for, cervical infection with 44 types of human papillomavirus (HPV) in a rural area in the Dindigul District, Tamil Nadu, India, we interviewed and obtained cervical cell samples from 1891 married women aged 16-59 years. HPV prevalence was 16.9% overall and 14.0% among women without cervical abnormalities, or 17.7 and 15.2%, respectively, age-standardised to the world standard population. In all, 21.9% of infections involved more than one HPV type. High-risk HPV types predominated, particularly HPV 16 (22.5% of women infected), followed by HPV 56, HPV 31, HPV 33 and HPV 18. Unlike most populations studied in developed countries, HPV prevalence was constant across the age groups. HPV positivity was inversely associated with education level (odds ratio (OR) among women with high school vs no education=0.6) and positively associated with widowhood and divorce (OR=1.7), nulligravidity (OR=2.3), and condom use (OR=2.6). It is unclear how much low clearance of, or frequent reinfection with HPV accounted for the study prevalence of infection in different age groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668709      PMCID: PMC2362069          DOI: 10.1038/sj.bjc.6602348

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


The prevalence of human papillomavirus (HPV) is low in some populations in Asia (Anh ) and Europe (de Sanjosé ), although it exceeds 15% in women aged 15–74 years in some parts of Latin America (Molano ) and sub-Saharan Africa (Thomas ), where incidence rates for cervical cancer are very high (Ferlay ). HPV prevalence shows different patterns of infection by age in different populations. Much higher HPV prevalences were generally found below age 25 (Molano ; Shin ; Peto ) or 35 years (Ronco ) than above these ages, but in a very high HPV-prevalence area (Ibadan, Nigeria), the proportion of HPV-positive women was similar in all 10-year age groups between 15 and 65 years or more (Thomas ). Information on HPV prevalence and type-specific distribution among Indian women is scanty (Duttagupta ). We have, therefore, carried out an HPV survey in a rural area in southern India.

MATERIALS AND METHODS

We carried out the present study between February and October 2003 in the Dindigul District, Tamil Nadu, India as a collaborative project between the Christian Fellowship Community Health Centre (CFCHC) and the International Agency for Research on Cancer (IARC). The study area is rural, at an average elevation of 600 m above sea level in the foothills of the Western Ghats and consists of 324 village panchayats (local administrative structures consisting of 4–23 villages). The study goal was to assess the prevalence of cervical HPV infection and cytological abnormalities in a sample of 2000 married, nonpregnant women aged 16–59 years, but we searched for an approximately two-fold larger population to compensate for ineligibility and refusals. We therefore randomly selected a few villages in the study district, as follows. After excluding the 113 village panchayats that participated in a concurrent IARC randomised trial of cervical visual screening (Sankaranarayanan ), we stratified the remaining village panchayats according to their total population (small: <3000; intermediate: 3000–5000; large: ⩾5000 people). We then randomly extracted nine small size, three intermediate size, and one-third of a large size village panchayat in order to obtain an approximately equal number of women from each stratum. The study working team, consisting of one medical doctor (R Rajkumar), three ad hoc trained nurses, and three healthcare workers, stayed in each selected village for 2–5 days and visited each household to invite eligible women. Women who agreed to participate signed informed consent forms as recommended by the ethics committees of the CFCHC and IARC, both of which approved this study. A structured questionnaire including information on sociodemographic characteristics, reproductive factors and use of contraceptive methods was administered in the local language (Tamil) in women's homes and an appointment was arranged in the temporary clinic that had been installed in each village during the survey.

Gynaecological examination and specimen collection

Women underwent a pelvic examination, performed by one of the three nurses. None had undergone a hysterectomy. Samples of exfoliated cells from the ecto- and endocervix were collected with a broom-type brush and placed in vials of PreservCyt solution, according to the manufacturer's instructions (Cytyc, Boxborough, MA, USA). All samples were stored at +4°C until shipment to the Department of Pathology at the Vrije University Medical Center, Amsterdam, The Netherlands, for HPV testing and liquid-based cytology. In order to meet the immediate screening needs of participating women, visual inspection with acetic acid and, in the presence of suspicious lesions, colposcopy, were performed (Sankaranarayanan ). Acetowhite lesions were treated, mainly with cryotherapy. Women with cervicovaginitis received antibiotic treatment. When cytology results became available, women with high-grade squamous intraepithelial lesions (HSIL) were recalled, biopsied and treated with cryotherapy or loop electrosurgical excision as appropriate.

Cytology

Liquid-based ThinPrep cytology slides were prepared from PreservCyt vial specimens according to the manufacturer's standard protocol. Results were classified by cytotechnicians according to the CISOE-A classification (Bulk ), and abnormal smears were reviewed by an experienced cytopathologist. Cytological evidence of infection with Trichomonas (T.) vaginalis was reported systematically.

Human papillomavirus detection techniques

To analyse the quality of the target DNA for polymerase chain reaction (PCR) testing, cervical specimens were screened with beta (β)-globin gene-specific primers. HPV positivity was assessed by general primer-mediated GP5+/GP6+-PCR and by hybridisation of PCR products in an enzyme immunoassay (EIA) using two HPV oligoprobe cocktails that, together, detect the following 44 HPV types: HPV 6, 11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 64, 66, 67, 68, 69, 70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to CP8304), 82 (IS39 and MM4 subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8), cand85, 86, cand89 (equivalent to CP6108) and JC9710. PCR products that were positive in the EIA were subsequently subjected to further typing by reverse line blot hybridisation, as described previously (van den Brule ). High-risk HPV types for this analysis included HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82 (Muñoz ). The group of low-risk types included all other HPV types.

Statistical analysis

Odds ratios (ORs) for HPV positivity with 95% confidence intervals (CIs) by various women's characteristics were calculated using unconditional, multiple logistic regression adjusted for age group (<25, 25–34, 35–44, 45–54, ⩾55 years). The statistical significance of trends for ORs was assessed by giving increasing scores to successive categories of appropriate variables in the logistic model.

RESULTS

Of the 2884 women invited, 154 could not be enrolled in the study because they were pregnant, 31 because of illness and 13 because of heavy menstrual bleeding, thus leaving 2686 eligible candidates. There were 743 refusals (27.7%) mainly because of lack of time (372) and reluctance to undergo a gynaecological examination (331). Women who refused to participate were similar to the participating ones in relation to their occupation, husband's occupation, religion, marital status, age at marriage, number of pregnancies and use of contraceptive methods. The only characteristics that were associated with refusals were age (highest below age 25 and above age 54) and education (with the minority of women with high school or college having a participation 10% lower than less educated women). Of the 1943 women who underwent a pelvic examination, 62 women had acetowhite lesions on visual inspection, 49 had inadequate cytology results and three had β-globin-negative HPV samples. Of the 1891 women with valid cytology and HPV results, 92 (4.9%) had abnormal cytological findings, including 46 with borderline dyskaryosis, 26 with mild dyskaryosis, 13 with moderate dyskaryosis and seven with severe dyskaryosis. Whereas the frequency of borderline dyskaryosis was similar in different age groups, moderate or severe dyskaryosis was never found in women under age 25, and steadily increased from age 25–34 (1.0%) to age 45–59 (2.3%, Figure 1). None of the study women reported previous cytological screening for cervical cancer.
Figure 1

Prevalence of dyskaryosis at liquid-based cytology by degree of dyskaryosis and by age group. (Dindigul, India).

The prevalence of HPV of any type was 16.9%, but it varied between 14.0% among cytologically normal women and 73.9% among those with cytological abnormalities (Table 1). The corresponding proportions age-standardised to the world population were 17.7% overall, 15.2% among those without and 64.9% among those with cytological abnormalities. In total, 250 women had single-type and 70 had multiple-type infection.
Table 1

Prevalence of various human papillomavirus (HPV) types by cytological findings and overall among 1891 women (Dindigul, India)

  Cytology
  Normal
Abnormal
Total
HPV typea Single Multiple Total (%) Single Multiple Total (%) Single Multiple Total (%)
Negative  1547 (85.9)  24b (26.1)  1571 (83.1)
Positive, any19953252 (14.0)511768 (73.9)25070320 (16.9)
High risk12547172 (9.6)491665 (70.7)17463237 (12.5)
Low risk6834102 (5.7)2911 (12.0)7043113 (6.0)
Uncharacterised6––6 (0.3)––––06––6 (0.3)
          
High risk          
 16302151 (2.8)15c6d21 (22.8)452772 (3.8)
 188715 (0.8)3e14 (4.3)11819 (1.0)
 26101 (0.1)000101 (0.1)
 3111314 (0.8)7d2e9 (9.8)18523 (1.2)
 338614 (0.8)44d8 (8.7)121022 (1.2)
 357714 (0.8)13d4 (4.4)81018 (1.0)
 394610 (0.6)01d1 (1.1)4711 (0.6)
 45336 (0.3)2d13 (3.3)549 (0.5)
 51538 (0.4)5e16 (6.5)10414 (0.7)
 5211213 (0.7)101 (1.1)12214 (0.7)
 53123 (0.2)011 (1.1)134 (0.2)
 5614519 (1.1)7d310 (10.9)21829 (1.5)
 58123 (0.2)31d4 (4.4)437 (0.4)
 5911112 (0.7)101 (1.1)12113 (0.7)
 66639 (0.5)000639 (0.5)
 73213 (0.2)000213 (0.2)
 82224 (0.2)000224 (0.2)
          
Low risk          
 6224 (0.2)011 (1.1)235 (0.3)
 30303 (0.2)011 (1.1)314 (0.2)
 32123 (0.2)000123 (0.2)
 40246 (0.3)000246 (0.3)
 42251237 (2.1)134 (4.4)261541 (2.2)
 43033 (0.2)022 (2.2)055 (0.3)
 44011 (0.1)000011 (0.1)
 54325 (0.3)000325 (0.3)
 55112 (0.1)000112 (0.1)
 67123 (0.2)022 (2.2)145 (0.3)
 69101 (0.1)000101 (0.1)
 70336 (0.3)000336 (0.3)
 81538 (0.4)022 (2.2)5510 (0.5)
 83101 (0.1)000101 (0.1)
 84112 (0.1)000112 (0.1)
 85505 (0.3)000505 (0.3)
 86202 (0.1)000202 (0.1)
 CP6108303 (0.2)000303 (0.2)
 JC97109918 (1.0)101 (1.1)10919 (1.0)

The same woman can appear more than once in ‘Multiple’ and ‘Total’ columns.

Includes three high-grade squamous intraepithelial lesions.

Includes six high-grade squamous intraepithelial lesions.

Includes one high-grade squamous intraepithelial lesion.

Includes two high-grade squamous intraepithelial lesions.

High-risk HPV types were substantially more frequent (12.5% of all women) than low-risk types (6.0%). Most commonly found in either single- or multiple-type infections were HPV 16 (3.8%), HPV 42 (a low-risk type, 2.2%), HPV 56 (1.5%), HPV 31 (1.2%), HPV 33 (1.2%) and HPV 18 (1.0%), but HPV type distribution varied by cytological results. High-risk types were found in 70.7% of women with cytological abnormalities and in 17 out of 20 (85.0%) women with moderate or severe dyskaryosis (including HPV 16 or 18 in nine women). Details of HPV types found in women with multiple HPV infections are given in Appendix A (Table A1). The prevalence of HPV (any type, high- and low-risk types, separately) was similar in women in different age groups (Figure 2, Table 2).
Table A1

Combinations of human papillomavirus (HPV) types in 70 women with multiple infections (Dindigul, India)

HPV type No. HPV type No. HPV type No.
 6,16116,JC97101 35,66 1
 6,181a 18,35 135,701
 6,56118,40135,811a
16,18 218,53,421 39,56 1
16,18,39 230,811a40,431
16,33 2a 31,33 1a40,54,591
16,33,39 1 31,39 1a42,431
16,35,40131,42142,512a
16,39 2 31,51 142,521
16,422 31,82 142,531
16,42,431a32,JC9710242,81,JC97101
16,51,55,66,JC97101 33,45 242,821
16,53 1a 33,52 143,452a
16,56 3a 33,56 2b54,581
16,673b33,JC9710158,84,JC97101
16,67,81135,422a66,JC97101
16,70135,42,56170,JC97101
16,73 135,441  
16,811 35,58 1a  

High-risk types in bold face.

One woman with abnormal cervical findings.

Two women with abnormal cervical findings.

Figure 2

Age-specific prevalence of cervical human papillomavirus (HPV) DNA. (Dindigul, India).

Table 2

Detection of cervical human papillomavirus (HPV) DNA according to sociodemographic characteristics among 1891 womena (Dindigul, India)

   HPV DNA positive
  
  Number of women Number (%) ORb (95% CI)
Age (years)      
 <25c33456(16.8)1 
 25–34847137(16.2)0.96(0.68–1.35)
 35–4444682(18.4)1.12(0.77–1.63)
 45–5422839(17.1)1.02(0.65–1.60)
 ⩾55366(16.7)0.99(0.39–2.50)
χ21 for trend   0.23P=0.63
      
Education      
 Illiteratec869158(18.2)1 
 Primary or secondary754128(17.0)0.91(0.70–1.19)
 High school or college26132(12.3)0.63(0.41–0.95)
χ21 for trend   4.00P=0.05
      
Occupation      
 Manual worker/farmer1022189(18.5)1.28(0.99–1.64)
 Housewifec812122(15.0)1 
 Others538(15.1)0.99(0.46–2.18)
      
Husband's occupation      
 Manual workerc1132192(17.0)1 
 Farmer43168(15.8)0.91(0.67–1.23)
 Others17224(14.0)0.79(0.50–1.25)
      
Religion      
 Hinduc1643284(17.3)1 
 Christian24036(15.0)0.83(0.57–1.21)
 Muslim60(0.0)0.00(0.00–∞)

Figures do not add up to the total because of missing values.

Adjusted for age.

Reference category; OR=Odds ratio; CI=Confidence interval.

Tables 2 and 3 show the relationship between HPV positivity and major characteristics of study women after adjustment for age. Education level was inversely associated with HPV prevalence (OR for women with high school or college degrees vs illiterate women=0.6; 95% CI: 0.4–1.0), whereas women working outside the house (the vast majority as farm labourers) had an excess of HPV positivity of borderline statistical significance (OR vs housewives=1.3; 95% CI: 1.0–1.6, Table 2). Husband's occupation and religion, which was Hinduism in the majority of study women, were not associated with HPV positivity (Table 2).
Table 3

Detection of cervical human papillomavirus (HPV) DNA according to marital status, reproductive factors, contraceptive use and Trichomonas vaginalis infection among 1891 womena (Dindigul, India)

   HPV DNA positive
  
  Number of women Number (%) ORb (95% CI)
Age at marriage (years)      
 ⩽15c35159(16.8)1 
 16–1752896(18.2)1.10(0.77–1.57)
 18–1956691(16.1)0.95(0.66–1.36)
 ⩾2043869(15.8)0.92(0.63–1.35)
χ21 for trend   0.57P=0.45
      
Marital status      
 Marriedc1767288(16.3)1 
 Widowed10726(24.3)1.66(1.03–2.67)
 Separated or divorced165(31.3)2.30(0.79–6.71)
      
Age at menarche (years)      
 ⩽12c33258(17.5)1 
 13–14887156(17.6)1.01(0.72–1.41)
 ⩾1562891(14.5)0.79(0.55–1.14)
χ21 for trend   2.15P=0.14
      
Number of pregnancies      
 05917(28.8)2.31(1.26–4.22)
 1–2c848128(15.1)1 
 3–4749137(18.3)1.22(0.92–1.62)
 ⩾523538(16.2)1.03(0.66–1.60)
χ21 for trend   0.09P=0.76
      
Contraceptive method      
 Nonec657118(18.0)1 
 Tubal ligation1183189(16.0)0.85(0.65–1.11)
 Condom3011(36.7)2.63(1.22–5.68)
 Othersd131(7.7)0.38(0.05–2.95)
      
Trichomonas vaginalis infection      
 Negativec1777294(16.5)1 
 Positive11426(22.8)1.48(0.94–2.34)

Figures do not add up to the total because of missing values.

Adjusted for age.

Reference category.

Including seven users of oral contraceptives and six users of intrauterine device; OR=Odds ratio; CI=confidence interval.

Women who were widowed (OR=1.7; 95% CI: 1.0–2.7), and separated or divorced (OR=2.3; 95% CI: 0.8–6.7) showed a higher proportion of HPV positivity than married women (Table 3). The median age at marriage was 18 years (range=12–33) and the median number of pregnancies was three (range=0–14). The median age at first pregnancy was 19 years (range=13–34). Child deliveries after age 30 were reported by only 5.9% of women. Age at first marriage and number of pregnancies among ever-pregnant women were unrelated to HPV positivity, although an OR of 2.3 (95% CI: 1.3–4.2) was found among the few nulligravidae (3% of all study women). Spontaneous or voluntary abortions were reported by 21.6% of HPV-negative and 25.9% of HPV-positive women (data not shown). Among contraceptive methods, only tubal ligation was reported often (63% of study women) and was unrelated to HPV positivity. An increased risk of HPV positivity was found, however, among 30 women who reported condom use (OR=2.6; 95% CI: 1.2–5.7). Finally, cytological evidence of infection with T. vaginalis was found in 6.0% of study women and was associated with an OR for HPV positivity of 1.5 (95% CI: 0.9–2.3, Table 3). When education level, marital status, number of pregnancies, and contraceptive methods were included, in addition to age, in the same multiple logistic regression, the corresponding ORs did not change materially.

DISCUSSION

The main findings of our large survey in Dindigul District in rural India are the high overall prevalence of HPV infection, the similar prevalence across different age groups, and the marked predominance of HPV 16 among HPV types. All-age HPV prevalence in Dindigul District is similar to that found in high-risk areas for cervical cancer in Latin America (Molano ; Matos ), although lower than in some parts of sub-Saharan Africa (Thomas ). No clear peak in HPV prevalence was found in young women in Dindigul District, whereas in most countries studied so far the prevalence of HPV below age 25 is ⩾2-fold higher than at 45 or above (Molano ; Peto ). However, a constant prevalence of HPV across age groups has been recently reported in Nigeria (Thomas ), suggesting that in some poor countries the risk of HPV infection is similar in different generations of women in contrast to the markedly higher HPV prevalence among younger women in many developed countries (Peto ). Low rates of HPV clearance and frequent HPV reinfections may also contribute to the steady age pattern observed in Dindigul District and Nigeria (Thomas ). India shows some of the highest rates of cervical cancer worldwide (Ferlay ), particularly in rural areas (Rajkumar ). The combined prevalence in a rural area of West Bengal of HPV types 16 and 18 in 534 Hindu women and 478 Muslim women was 7.5 and 9.6%, respectively (Duttagupta ). HPV 16 and 18 positivity was similar in four age groups (<25, 25–34, 35–44, ⩾45 years) among Muslim women, but steeply declined with age among Hindu women. Our survey is the first study to assess a broad range of HPV types in different age groups in India in a large sample of women. It showed that HPV 16 is the most frequently found type in the general population, affecting 22.5% of HPV-positive women. The corresponding percentages in IARC surveys in Asia and Africa were less than 14% (Shin ; Thomas ). The predominance of HPV 16 in the Indian population is similar to that found with the same PCR-assay in Europe (32.6%, Ronco ) and Latin America (22.0%, Molano ). Of note, a high proportion (63.2%) of cervical cancer specimens was also found to be positive for HPV 16 in India (Franceschi ). Among other HPV types, a relatively high frequency of HPV 42 and HPV 56 (the second most frequent high-risk type in Dindigul) was found in previous IARC surveys (Anh ; Thomas ). HPV 42 is a low-risk type while HPV 56 seems to be one of the high-risk types like HPV 31, 33, 35, 52, 53 and 58 that is substantially under-represented in invasive cancer compared to preinvasive cervical lesions (Clifford ). A strength of our survey in Dindigul District is a reliance on high-quality liquid-based cytology in a population that had never been screened before. Most previous surveys in developing countries (Duttagupta ), including those by IARC, had to rely on locally read cytology and indeed showed a much lower agreement between cytological findings and HPV results than in our present study, where 85% of moderate and severe dyskaryosis (corresponding to high-grade squamous intraepithelial lesions, HSIL) harboured high-risk HPV types. Moderate or severe dyskaryoses were never found below 25 years in Dindigul District, but their prevalence increased with age and in women aged 45 or older it was approximately four-fold greater than in women in the same age group in England (Department of Health, 2000). Only a few of the possible correlates of HPV positivity could be evaluated, since inclusion of unmarried women and questions about sexual habits were discouraged during our preparatory meetings with the village heads and local collaborators in Dindigul. The study took place, however, in a rather homogenous, low-income rural population and it is, therefore, not surprising that the very few characteristics that stood out as being directly (e.g., nulligravidity, widowhood or divorce, and condom use) or indirectly (high school or college degree) associated with HPV positivity involved a small, and sometimes very small, proportion of study women. The uniformity of living standards and lifestyle in rural India provides some reassurance in respect of selection bias. Two main groups of women accounted for nonparticipation in our study: those who were not traced during the few days that the gynaecological clinic stayed in each village (approximately 25% of women), and those who were contacted but refused to participate (an additional 19%) mainly out of a lack of familiarity with gynaecological examinations. However, we were able to obtain some basic information from almost all women during the survey, or in subsequent repeated visits to the same villages. The three main groups (participants, refusals, and untraced women) were similarly distributed by sociodemographic and reproductive factors.
  16 in total

1.  The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

Authors:  S Bulk; F J Van Kemenade; L Rozendaal; C J L M Meijer
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

2.  GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes.

Authors:  Adriaan J C van den Brule; René Pol; Nathalie Fransen-Daalmeijer; Leo M Schouls; Chris J L M Meijer; Peter J F Snijders
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Prevalence of human papillomavirus infection in women in Turin, Italy.

Authors:  Guglielmo Ronco; Valeria Ghisetti; Nereo Segnan; Peter J F Snijders; Anna Gillio-Tos; Chris J L M Meijer; Franco Merletti; Silvia Franceschi
Journal:  Eur J Cancer       Date:  2005-01       Impact factor: 9.162

4.  Are Muslim women less susceptible to oncogenic human papillomavirus infection? A study from rural eastern India.

Authors:  C Duttagupta; S Sengupta; M Roy; D Sengupta; P Bhattacharya; P Laikangbam; S Roy; S Ghosh; R Das
Journal:  Int J Gynecol Cancer       Date:  2004 Mar-Apr       Impact factor: 3.437

5.  Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study.

Authors:  Silvia Franceschi; Thangarajan Rajkumar; Salvatore Vaccarella; Vendhan Gajalakshmi; Ajit Sharmila; Peter J F Snijders; Nubia Muñoz; Chris J L M Meijer; Rolando Herrero
Journal:  Int J Cancer       Date:  2003-10-20       Impact factor: 7.396

6.  Human papillomavirus infection among women in South and North Vietnam.

Authors:  Thi Hoang Anh Pham; Trong Hieu Nguyen; Rolando Herrero; Salvatore Vaccarella; Jennifer S Smith; Thi Thuy Nguyen Thuy; Hoai Nga Nguyen; Ba Duc Nguyen; Rhoda Ashley; Peter J F Snijders; Chris J L M Meijer; Nubia Muñoz; D Max Parkin; Silvia Franceschi
Journal:  Int J Cancer       Date:  2003-03-20       Impact factor: 7.396

7.  Cervical human papillomavirus infection in the female population in Barcelona, Spain.

Authors:  Silvia de Sanjose; Rosa Almirall; Belen Lloveras; Rebeca Font; Mireia Diaz; Nubia Muñoz; Isabel Català; Chris J L M Meijer; Peter J F Snijders; Rolando Herrero; F Xavier Bosch
Journal:  Sex Transm Dis       Date:  2003-10       Impact factor: 2.830

8.  Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study.

Authors:  J O Thomas; R Herrero; A A Omigbodun; K Ojemakinde; I O Ajayi; A Fawole; O Oladepo; J S Smith; A Arslan; N Muñoz; P J F Snijders; C J L M Meijer; S Franceschi
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

9.  Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort.

Authors:  J Peto; C Gilham; J Deacon; C Taylor; C Evans; W Binns; M Haywood; N Elanko; D Coleman; R Yule; M Desai
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

10.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.

Authors:  G M Clifford; J S Smith; M Plummer; N Muñoz; S Franceschi
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more
  37 in total

1.  The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies.

Authors:  Julia C Gage; Kayode O Ajenifuja; Nicolas A Wentzensen; Akinfolarin C Adepiti; Claire Eklund; Mary Reilly; Martha Hutchinson; Sholom Wacholder; Joe Harford; Amr S Soliman; Robert D Burk; Mark Schiffman
Journal:  Int J Cancer       Date:  2011-08-05       Impact factor: 7.396

2.  High prevalence of oncogenic HPV-16 in cervical smears of asymptomatic women of eastern Uttar Pradesh, India: a population-based study.

Authors:  Shikha Srivastava; Sadhana Gupta; Jagat Kumar Roy
Journal:  J Biosci       Date:  2012-03       Impact factor: 1.826

Review 3.  Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness.

Authors:  I Mattheij; A M Pollock; P Brhlikova
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

4.  Condom use and human papillomavirus in men.

Authors:  Susan Hariri; Lee Warner
Journal:  J Infect Dis       Date:  2013-05-03       Impact factor: 5.226

5.  Prevalence of Human Papilloma Virus Infection in Young Primiparous Women During Postpartum Period: Study from a Tertiary Care Center in Northern India.

Authors:  Alpana Garg; Vanita Suri; Raje Nijhawan; Neelam Aggarwal; Ritu Aggarwal; Charu Guleria; Mili Thakur
Journal:  J Clin Diagn Res       Date:  2016-10-01

6.  Detection of human papillomavirus in women attending Pap cervical screening camp at a peripheral hospital of North-Eastern India.

Authors:  Sibnarayan Datta; Manisha Agarwal; Soumya Chatterjee; Hemanta Kumar Gogoi; Vijay Veer; Lokendra Singh
Journal:  Med J Armed Forces India       Date:  2013-08-05

7.  Human papillomavirus infection in women with and without cervical cancer in Karachi, Pakistan.

Authors:  S A Raza; S Franceschi; S Pallardy; F R Malik; B I Avan; A Zafar; S H Ali; S Pervez; S Serajuddaula; P J F Snijders; F J van Kemenade; C J L M Meijer; S Shershah; G M Clifford
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

8.  Human papillomavirus-type distribution in women with and without cervical neoplasia in north India.

Authors:  Neerja Bhatla; Lalit Dar; A Rajkumar Patro; Pankaj Kumar; Sunil K Pati; Alka Kriplani; Arti Gulati; Shobha Broor; Venkateswaran K Iyer; Sandeep Mathur; Keerti V Shah; Patti E Gravitt
Journal:  Int J Gynecol Pathol       Date:  2008-07       Impact factor: 2.762

Review 9.  Worldwide impact of the human papillomavirus vaccine.

Authors:  Amy A Hakim; Tri A Dinh
Journal:  Curr Treat Options Oncol       Date:  2009-04-23

10.  HPV infection in women with and without cervical cancer in Conakry, Guinea.

Authors:  N Keita; G M Clifford; M Koulibaly; K Douno; I Kabba; M Haba; B S Sylla; F J van Kemenade; P J F Snijders; C J L M Meijer; S Franceschi
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.